 |
 |
|
CME Information
|
  |
This CME-certified Web-based enduring activity contains highlights from the 2007 Perspectives in Central Nervous System Malignancies III conference held March 30–31, 2007 in Warsaw, Poland.
Release date: August 2007
Expiration date: August 31, 2008
Estimated time to complete activity: Up to 4.5 hours
Sponsored by
Support for this activity has been provided through an educational grant from
Activity Overview
The 2007 Perspectives in Central Nervous System Malignancies III conference served as a venue to discuss the most recent findings regarding the diagnosis and treatment of a wide range of CNS malignancies. This Web activity highlight the important aspects of each clinical presentation with insights from the conference co-chairs.
Target Audience
This activity has been designed to meet the educational needs of neuro-oncologists, radiation oncologists, neurosurgeons, neurologists, pathologists, and other health care professionals who treat patients with CNS malignancies and/or secondary brain metastases.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Comment on the newest trends in imaging and their role in the diagnosis and monitoring of disease progression as it relates to CNS malignancies
- Discuss state-of-the-art advancements in neurosurgery for CNS malignancies
- Evaluate novel treatment strategies and newly approved agents for high-grade gliomas
- Describe the heterogeneity within these tumor types and the key factors to consider when developing individual patient treatment plans
- Identify expected outcomes and toxicities of standard therapies
- Recognize quality-of-life issues and incorporate them into management strategies
- Utilize the most up-to-date treatment strategies for CNS malignancies
- Identify the major changes associated with the updated 2007 WHO guidelines
- Discuss the potential clinical implications of the various genetic or molecular alterations that are associated with certain tumor types
- Determine how tumor phenotypes influence prognosis
- Determine the most effective treatment strategies for both newly diagnosed and recurrent primary CNS lymphoma
- Describe the epidemiology and current state of treatment for rare CNS malignancies
- Identify the molecular mechanisms for resistance to chemotherapy in the treatment of malignant CNS tumors
- Identify prognostic factors in CNS malignancies that influence treatment outcomes
| W. K. Alfred Yung, MD View Bio Chairman, Department of Neuro-Oncology Professor of Neurology Margaret and Ben Love Chair of Clinical Cancer Care University of Texas M. D. Anderson Cancer Center Houston, Texas |
 |
| Martin J. van den Bent, MD View Bio Department of Neuro-Oncology Daniel den Hoed Cancer Center Rotterdam, Netherlands |
 |
Accreditation Statement
Curatio CME Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
Curatio CME Institute designates this educational activity for a maximum of 4.5 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Physicians should not claim credit for this activity if credit was previously claimed for the conference on which this Web activity is based.
Method of Participation
There are no fees for participating in this CME activity. To receive credit during the period August 2007 to August 31, 2008, participants must (1) read the learning objectives and disclosure statements, (2) study the educational activity, (3) complete the posttest, and (4) complete the activity evaluation form, including the certificate information section.
You will then be able to print or store your AMA PRA Category 1 Credit certificate for this activity. Please e-mail any questions to cmeinfo@curatiocme.com.
Medium
The Internet was selected as the instructional format to accommodate the learning preferences of a significant portion of the target audience.
Disclosure
In accordance with the ACCME’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:
W. K. Alfred Yung, MD has disclosed the following relevant financial relationship(s):
Speaker Schering-Plough
Consultant Eli Lilly, Myriad, Novartis, Schering-Plough
Dr. Yung discusses the unlabeled or investigational use of a commercial product.
Martin J. van den Bent, MD has disclosed the following relevant financial relationship(s):
Speaker Schering-Plough
Consultant Novartis, Schering-Plough
Dr. van den Bent discusses the unlabeled or investigational use of a commercial product.
Curatio CME Institute
Thomas Finnegan, PhD, Medical Writer, has disclosed no relevant financial relationships.
Denise C. LaTemple, PhD, Vice President, Scientific Services, has disclosed no relevant financial relationships.
Brett Mutschler, CME Director, has disclosed no relevant financial relationships.
Jonathan S. Simmons, ELS, Managing Editor, has disclosed no relevant financial relationships.
Disclaimer
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Curatio CME Institute and Schering-Plough do not recommend the use of any agent outside the labeled indications.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Curatio CME Institute or Schering-Plough. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Generic Name |
Trade Name |
Approved Use (if any) |
Unapproved/ |
AP 12009 |
N/A |
N/A |
Recurrent high-grade gliomas |
Bevacizumab |
Avastin® |
In combination with intravenous 5-fluorouracil–based chemotherapy, In combination with carboplatin and paclitaxel, indicated for first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non-squamous, non–small cell lung cancer |
In combination with irinotecan for recurrent GBM or unresectable glioma |
Dexamethasone |
Decadron® |
Indicated for the palliative care of adult leukemia/lymphoma and acute leukemia of childhood |
In combination with temozolomide for relapsed anaplastic oligoastrocytoma |
Methotrexate |
Trexall® |
Indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens, and hydatidiform mole Can be used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides, (cutaneous T-cell lymphoma), lung cancer, and advanced non-Hodgkins lymphomas Indicated for the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy, but only when diagnosis has been established, as by biopsy or after dermatologic consultation Indicated for the management of selected adults with severe, active, rheumatoid arthritis (ARC criteria), or children with polyarticular-course juvenile rheumatoid arthritis, who have had insufficient therapeutic response to or are intolerant of an adequate trial of first-line therapy, including full dose nonsteroidal anti-inflammatory agents |
Alone or combined with chemotherapy in first-line primary CNS lymphoma |
Irinotecan |
Camptosar® |
Indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum Used for recurrent or progressive metastatic carcinoma of the colon or rectum following initial fluorouracil-based therapy |
In combination with bevacizumab for recurrent GBM or unresectable glioma |
Topotecan |
Hycamtin® |
For the treatment of metastatic carcinoma of the ovary after failure of initial or subsequent chemotherapy. Indicated for small cell lung cancer after failure of first-line chemotherapy. For the treatment of stage IV-B, recurrent, or persistant carcinoma of the cervix that is not amenable to curative treatment with surgery and/or radiation therapy |
Single agent for salvage primary CNS lymphoma |
Rituximab |
Rituxan® |
For the treatment of relapsed/refractory low-grade or follicular, CD20-positive, B-cell non-Hodgkin’s lymphoma First-line treatment for follicular, CD20-positive, B-cell, non-Hodgkin’s lymphoma in combination with CVP chemotherapy For treatment of low-grade, CD20-positive, B-cell non-Hodgkin’s lymphoma in patients with stable disease or who achieve a partial or complete response to first-line CVP chemotherapy For the first-line treatment of diffuse large B-cell, CD20-positive, non-Hodgkin’s lymphoma in combination with CHOP or other anthracycline-based chemotherapy regimens Indicated for use with methotrexate to reduce the signs and symptoms in adult patients of moderate to severe rheumatoid arthritis in patients with an inadequate response to one or more tumor necrosis factor antagonist therapies |
In combination with temozolomide for salvage primary CNS lymphoma |
Gabapentin |
Neurontin® |
Indicated for the management of postherpetic neuralgia in adults and as adjunctive therapy of partial seizures with and without secondary generalization in patients >12 years of age with epilepsy Indicated as adjunctive therapy for partial seizures in pediatric patients 3–12 years old |
Seizure prevention in patients with brain tumors |
Levetiracetam |
KeppraTM |
Indicated as adjunctive therapy in the treatment of partial-onset seizures in adult epileptics |
Seizure prevention in patients with brain tumors |
Temozolomide
|
Temodar® |
For the treatment of adult patients with newly diagnosed GBM concomitantly with radiotherapy and then as maintenance treatment. For the treatment of adult patients with refractory anaplastic astrocytoma. |
As a single agent for patients with grade 2 gliomas As a single agent or in combination with rituximab for salvage primary CNS lymphoma In combination with dexamethasone for relapsed anaplastic oligoastrocytoma As a single agent for newly diagnosed gliomatosis cerebri; as a single agent for ependymoma salvage therapy |
Etoposide |
VePesid® |
For the treatment of small cell lung cancer as a first-line therapy in combination with other approved chemotherapy agents |
In combination with ifosfamide and cytarabine for salvage primary CNS lymphoma |
Ifosfamide |
Ifex® |
Indicated as third-line treatment in combination with other approved chemotherapy agents for germ cell testicular cancer |
In combination with VP-16 or cytarabine for salvage primary CNS lymphoma |
Cytarabine |
Cytosar-U® |
In combination with other anticancer drugs, indicated for induction remission in acute nonlymphocytic leukemia of adults and children. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia Intrathecal administration of cytarabine is indicated in the prophylaxis and treatment of meningeal leukemia |
In combination with ifosfamide or VP-16 for salvage primary CNS lymphoma |
Procarbazine |
Matulanea® |
To be used in combination with other anticancer drugs for the treatment of stage III and IV Hodgkin’s disease |
In combination with lomustine and vincristine for newly diagnosed oligodendroglioma; grade 2 glioma; anaplastic oligoastrocytoma; newly diagnosed gliomatosis cerebri |
Lomustine |
CeeNU® |
Used as a monotherapy or in combination with other approved chemotherapeutic agents for the treatment of primary and metastatic brain tumors in patients who have already received surgery and/or radiotherapy Indicated for use as secondary therapy in combination with other approved chemotherapy agents for patients with Hodgkin’s disease who relapse while receiving or fail to respond to primary therapy |
In combination with procarbazine and vincristine for newly diagnosed oligodendroglioma; grade 2 glioma; anaplastic oligoastrocytoma; newly diagnosed gliomatosis cerebri |
Vincristine |
Vincasar PFS® |
Indicated for the treatment of acute leukemia. This agent has also been shown useful in combination with other oncologic agents in Hodgkin’s disease, non-Hodgkin’s malignant lymphomas (lymphocytic, mixed-cell, histocytic, undifferentiated, nodular, and diffuse types), rhabdomyosarcoma, neuroblastoma, and Wilms’ tumor |
In combination with lomustine and procarbazine for newly diagnosed oligodendroglioma; grade 2 glioma; anaplastic oligoastrocytoma; newly diagnosed gliomatosis cerebri |
Computer Requirements
- Javascript-enabled browser
- Active Internet Connection
- Adobe Acrobat Reader Plugin
- Adobe Flash Player Plugin v.8.0+
Privacy Policy
Curatio CME Institute collects the information provided by the user. The information is used to provide notification about upcoming programs and educational information that may be of interest to our users. The information is not shared with others for commercial purposes, unless prior permission has been granted by the user.
Curatio CME Institute may collect standard Web traffic data such as the time and date of visit. We use this information to administer our Web site. Browsing activity is recorded to form aggregate and anonymous demographic information, which is used as described above. Curatio CME Institute does not sell or offer to sell any user data, including registration and billing information, to any third parties for commercial purposes. Curatio CME Institute does, when required, provide the minimum subset of information to third parties that are responsible for accreditation and issuance of certification of CME/CE tests submitted. By participating in the Web-based activity, you agree that Curatio CME Institute has full permission to provide this minimum subset of information to third parties as required by law.
